Brief: Protagonist Therapeutics Q3 EPS USD -0.62
06/11/2025 21:05
Nov 06 (Reuters) - Protagonist Therapeutics Q3 net income USD -39.339 million. Q3 license and collaboration revenue USD 4.712 million Q3 income from operations USD -46.421 million Q3 operating expenses USD 51.133 million
Recent news on Protagonist Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI International
US FDA approves Takeda, Protagonist's drug for rare blood cancer (updated)
US FDA approves Takeda, Protagonist's drug for rare blood cancer
Silence Therapeutics jumps after mid-stage trial data for blood cancer drug
Protagonist Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary